In an effort to focus on its preclinical targeted therapeutics, SuperGen Inc. decided to sell the North American rights to Nipent and SurfaceSafe to Mayne Pharma Ltd. in a deal worth $34 million. (BioWorld Today)

Completing its planned exit from small-molecule development, Celera Genomics sold its cathepsin S inhibitor program to Schering AG in a deal worth up to $365 million. (BioWorld Today)

Less than three months after signing its first major preclinical deal focused on infectious disease, PTC Therapeutics Inc. topped it with a new cardiovascular collaboration worth up to $345 million with CV Therapeutics Inc. (BioWorld Today)